


Patient Data		Healthcare Provider		Sample Data	
Name	Boris	Name	Name of contact person	Sample Id	recommendation-English-3-14
Patient Id	19501201-XXXX	Organization	Biomedical	Test Date	December, 2022
Birth Date		Customer Id	A3P000000001	Answer Date	12 December, 2022



Stockholm3 Recommendation

Increased risk for prostate cancer: Referral to urologist is recommended. mpMRI is recommended if prostate volume is less than 35 cc or prostate digital rectal exam is abnormal. Otherwise, follow-up testing is recommended within 2 years.

Report Manager: Per Venge, Licensed physician

The Stockholm3 test is a diagnostic test for estimating the risk for prostate cancer. The Stockholm3 test combines five plasma proteins (tPSA, fPSA, KLK2, PSP94, GDF15), more than 100 genetic markers and clinical data (age, previous biopsy findings, family history and use of 5-alpha-reductase inhibitors) to estimate the risk for significant cancer.

For this Reply, the laboratory uses RSE-B, a CE-marked medical device software product, provided by A3P Biomedical AB (Org.nr: 559163-0255). The Instructions for Use for RSE-B, I FU RSE-B version 2, is available for download at <https://a3pbiomedical.com/IFU>.

RSE-B is based on the ST HLM3-MRI study, published by Nordström et al in The Lancet Oncology 2021 and ST HLM3MR-2 study. RSE-B was validated for men aged 45-74 years and shall not be used for men who already are diagnosed with prostate cancer. A Stockholm3 Risk Score $\geq 11\%$ is considered as increased risk for clinically significant prostate cancer. The reported "Calculated Age" is the patient's age at the date for blood sampling.

A3P Lab AB is registered in Sweden and works in compliance to the Swedish Patient Safety Act 2010:659. A3P Lab AB, Vallongatan 1, 752 28 Uppsala. Org.nr: 559163-0255. SP EC -0003-05